SIBO: Small Intestinal Bacterial Overgrowth—A Real Disease or a Commercial Label?
In this article
Our digestive system is a complex ecosystem hosting trillions of microorganisms. In healthy people, most bacteria live in the large intestine (colon), while digestive enzymes and rapid transit (motility) keep the small intestine relatively sparsely populated. Sometimes this balance breaks down: colonic bacteria migrate into the small intestine and multiply excessively. In medical terminology, this is Small Intestinal Bacterial Overgrowth (SIBO) . The Turkish term means “bacterial overgrowth in the small intestine.”
Promoted on social media and popular health platforms as “the cause of every bloated abdomen,” SIBO has become confusing for patients and physicians alike. This review examines its biological definition, controversies over diagnosis (breath testing vs aspiration), its complex relationship with irritable bowel syndrome (IBS), and evidence-based treatment protocols in light of current literature.
Definition and Clinical Presentation
According to the North American Consensus and American College of Gastroenterology (ACG) guidelines, SIBO is bacterial growth of ≥10³ CFU/mL (1000 colony-forming units per milliliter) in a small-intestinal aspirate. These bacteria ferment nutrients, producing gases such as hydrogen and methane.
- Gastrointestinal: Excessive gas, bloating (distension), abdominal pain, diarrhea, or constipation.
- Systemic: Chronic fatigue, brain fog, joint pain (controversial).
- Severe Cases: Weight loss, B12 deficiency, fatty stools (steatorrhea).
Historical Evolution: Classical to Modern SIBO
1950-1990 (Classical Era): SIBO was considered rare, occurring only in patients with serious anatomical abnormalities (gastric surgery, blind loop syndrome, scleroderma, diabetic neuropathy), with severe malabsorption and weight loss.
2000-Present (Modern Era): The definition broadened. SIBO is now investigated as a cause of bloating and gas in IBS patients without obvious structural abnormalities. A 2020 meta-analysis found SIBO positivity in 35% of IBS patients, 4-5 times more often than in healthy controls.
Diagnostic Methods: Is There a Gold Standard?
Diagnosis is difficult because the “gold standard” is invasive, while practical methods have error margins.
| Method | Advantages | Disadvantages and Risks |
|---|---|---|
| Jejunal Aspirate Culture (Endoscopic) |
Direct bacterial count. The most reliable method (≥10³ CFU/mL). |
Invasive (requires endoscopy). Expensive. May miss bacteria that do not grow in culture. |
| Breath Tests (Lactulose / Glucose) |
Noninvasive, inexpensive, and easy. Can also measure methane production (IMO). |
High False-Positive Rate: With rapid intestinal transit, SIBO may be suspected before the sugar reaches the colon. Standardization is problematic. |
Treatment: Antibiotics and Beyond
The aim is to reduce bacteria, not eliminate them entirely (sterilization). The most commonly used agent is Rifaximin(3x550 mg daily for 14 days). Because it is not absorbed from the intestine, systemic side effects are minimal.
Evidence: A 2024 meta-analysis (6 RCTs) found antibiotics were 2.5 times more likely than placebo to improve symptoms. Rifaximin significantly reduces bloating in a subgroup of IBS patients.
Recurrence is the greatest challenge. Even after a successful antibiotic course, SIBO returns:
- Within 3-6 months in 1/3 of patients,
- Within 9 months in 43.7% of patients .
Antibiotics alone are therefore insufficient; the underlying cause (e.g., low stomach acid or impaired motility) must be addressed.
Low-FODMAP Diet: Restricting fermentable carbohydrates can reduce gas and bloating by cutting off bacterial food. However, prolonged restriction may reduce microbiota diversity, so dietitian supervision is needed.
Probiotics: ACG guidelines do not routinely recommend probiotics for SIBO treatment. They may worsen symptoms in some patients by further increasing bacterial load.
The Major Debate: A Real Disease or Overdiagnosis?
Influenced by social media, patients with bloating diagnose themselves with SIBO. Yet bloating may arise from food intolerance, visceral hypersensitivity, or pelvic floor dysfunction. Low breath-test specificity can label healthy people as ill.
Modern aspirate analyses, such as the REIMAGINE study, have demonstrated increased bacteria such as E. coli and Klebsiella in patients diagnosed with SIBO, associated with symptoms. The problem is therefore not the disease itself but limitations in diagnostic methods.
Drozdogan Academy Commentary
“SIBO is neither a myth to dismiss entirely nor the sole cause of every abdominal pain. It is real and treatable, particularly with risk factors such as diabetes, prior surgery, or scleroderma.
Our warning to patients is this: do not diagnose yourself with SIBO from internet information or use antibiotics or herbal remedies indiscriminately. That may cause more lasting damage to gut flora. A gastroenterologist must diagnose it by considering clinical findings and test results together.”
Scientific References
- Quigley E. Re-examining Small Intestinal Bacterial Overgrowth: Caution in Overreliance on Breath Tests. Houston Methodist Leading Medicine Blog. 2025.
- GMFH Editing Team. Certainties and uncertainties of SIBO. Gut Microbiota for Health. 2024.
- Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178.
- Shah A, et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020.
- Lauritano EC, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031-5.
- Shah A, et al. Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2024.
- Mayo Clinic Staff. An updated appraisal of the SIBO hypothesis and the limits of breath testing. Mayo Clinic News. 2024.
- Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry. 2020.
- Rezaie A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017.
- Pimentel M, et al. Methanogens in Human Health and Disease. Am J Gastroenterol Suppl. 2012.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.